0001209191-17-067087.txt : 20171222
0001209191-17-067087.hdr.sgml : 20171222
20171222165929
ACCESSION NUMBER: 0001209191-17-067087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171221
FILED AS OF DATE: 20171222
DATE AS OF CHANGE: 20171222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harr Steve
CENTRAL INDEX KEY: 0001627387
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36781
FILM NUMBER: 171273192
MAIL ADDRESS:
STREET 1: 307 WESTLAKE AVE. NORTH, STE. 300
CITY: SEATTLE
STATE: WA
ZIP: 98109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Juno Therapeutics, Inc.
CENTRAL INDEX KEY: 0001594864
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463656275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 2065821600
MAIL ADDRESS:
STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200
CITY: SEATTLE
STATE: WA
ZIP: 98109
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-12-21
0
0001594864
Juno Therapeutics, Inc.
JUNO
0001627387
Harr Steve
C/O 400 DEXTER AVENUE NORTH
SUITE 1200
SEATTLE
WA
98109
0
1
0
0
CFO & Head, Corp. Development
Common Stock
2017-12-21
4
M
0
8750
8.72
A
772082
D
Common Stock
2017-12-21
4
S
0
8250
44.7373
D
763832
D
Common Stock
2017-12-21
4
S
0
500
45.182
D
763332
D
Stock Option (Right to Buy)
8.72
2017-12-21
4
M
0
8750
0.00
D
2024-11-13
Common Stock
8750
98750
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015.
This transaction was executed in multiple trades at prices ranging from $44.15 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $45.15 to $45.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
1/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter.
/s/ Zachary D. Hale, attorney-in-fact
2017-12-22